Mitomycin-C, 5-fluorouracil, and leucovorin as a salvage therapy in patients with metastatic colorectal adenocarcinoma
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Kang, Eun Joo | - |
dc.contributor.author | Choi, Yoon Ji | - |
dc.contributor.author | Kim, Jung Seon | - |
dc.contributor.author | Kim, Seung Tae | - |
dc.contributor.author | Park, Kyong Hwa | - |
dc.contributor.author | Choi, In Keun | - |
dc.contributor.author | Oh, Sang Chul | - |
dc.contributor.author | Seo, Jae Hong | - |
dc.contributor.author | Shin, Sang Won | - |
dc.contributor.author | Kim, Jun Suk | - |
dc.contributor.author | Kim, Yeul Hong | - |
dc.date.accessioned | 2021-09-07T22:23:26Z | - |
dc.date.available | 2021-09-07T22:23:26Z | - |
dc.date.created | 2021-06-14 | - |
dc.date.issued | 2010-12 | - |
dc.identifier.issn | 1743-7555 | - |
dc.identifier.uri | https://scholar.korea.ac.kr/handle/2021.sw.korea/115182 | - |
dc.description.abstract | Aim: There is no further treatment option for metastatic colon patients who are refractory to standard chemotherapy and to whom novel biological agents are not available. We evaluated the outcomes of mitomycin-C, 5-fluorouracil (5-FU) and leucovorin in patients with metastatic colon cancer previously treated with oxaliplatin/5-FU/leucovorin and irinotecan/5-FU/leucovorin. Methods: We retrospectively analyzed 46 patients who had received mitomycin-C/5FU/leucovorin between March 2008 and December 2009. All patients had failed prior first-line and second-line therapy containing oxaliplatin, irinotecan, and 5-FU. Results: The median age of the patients was 57.0 years (range, 34.0-76.0) and their median Eastern Cooperative Oncology Group performance status was 1 (0-2). A complete or partial response was not observed in any patient and stable disease was observed in 19 patients (41.3%). The median duration of follow up was 29 weeks (range 8-87 weeks). Median progression-free survival was 10 weeks (95% CI 8-12) and median overall survival was 38 weeks (95% CI 32-44). Grade 3 and 4 hematological toxicities included neutropenia in five patients (10.8%) and thrombocytopenia in four patients (8.8%). Grade 3 or 4 non-hematologic toxicities included nausea and vomiting in two patients. There were no treatment-related deaths. Conclusion: The combination regimen of mitomycin-C/5-FU/leucovorin showed marginal activity and tolerable toxicity profiles in heavily pretreated metastatic colorectal cancer patients. | - |
dc.language | English | - |
dc.language.iso | en | - |
dc.publisher | WILEY | - |
dc.subject | 3RD-LINE CHEMOTHERAPY | - |
dc.subject | PROGNOSTIC-FACTOR | - |
dc.subject | PLUS IRINOTECAN | - |
dc.subject | CANCER PATIENTS | - |
dc.subject | PHASE-III | - |
dc.subject | CETUXIMAB | - |
dc.subject | CAPECITABINE | - |
dc.subject | OXALIPLATIN | - |
dc.subject | CARCINOMA | - |
dc.subject | FLUOROURACIL | - |
dc.title | Mitomycin-C, 5-fluorouracil, and leucovorin as a salvage therapy in patients with metastatic colorectal adenocarcinoma | - |
dc.type | Article | - |
dc.contributor.affiliatedAuthor | Choi, Yoon Ji | - |
dc.contributor.affiliatedAuthor | Kim, Jung Seon | - |
dc.contributor.affiliatedAuthor | Park, Kyong Hwa | - |
dc.contributor.affiliatedAuthor | Choi, In Keun | - |
dc.contributor.affiliatedAuthor | Oh, Sang Chul | - |
dc.contributor.affiliatedAuthor | Seo, Jae Hong | - |
dc.contributor.affiliatedAuthor | Shin, Sang Won | - |
dc.contributor.affiliatedAuthor | Kim, Jun Suk | - |
dc.contributor.affiliatedAuthor | Kim, Yeul Hong | - |
dc.identifier.doi | 10.1111/j.1743-7563.2010.01334.x | - |
dc.identifier.scopusid | 2-s2.0-78649783656 | - |
dc.identifier.wosid | 000284771500008 | - |
dc.identifier.bibliographicCitation | ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, v.6, no.4, pp.286 - 291 | - |
dc.relation.isPartOf | ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY | - |
dc.citation.title | ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY | - |
dc.citation.volume | 6 | - |
dc.citation.number | 4 | - |
dc.citation.startPage | 286 | - |
dc.citation.endPage | 291 | - |
dc.type.rims | ART | - |
dc.type.docType | Article | - |
dc.description.journalClass | 1 | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.relation.journalResearchArea | Oncology | - |
dc.relation.journalWebOfScienceCategory | Oncology | - |
dc.subject.keywordPlus | 3RD-LINE CHEMOTHERAPY | - |
dc.subject.keywordPlus | PROGNOSTIC-FACTOR | - |
dc.subject.keywordPlus | PLUS IRINOTECAN | - |
dc.subject.keywordPlus | CANCER PATIENTS | - |
dc.subject.keywordPlus | PHASE-III | - |
dc.subject.keywordPlus | CETUXIMAB | - |
dc.subject.keywordPlus | CAPECITABINE | - |
dc.subject.keywordPlus | OXALIPLATIN | - |
dc.subject.keywordPlus | CARCINOMA | - |
dc.subject.keywordPlus | FLUOROURACIL | - |
dc.subject.keywordAuthor | 5-FU | - |
dc.subject.keywordAuthor | leucovorin | - |
dc.subject.keywordAuthor | mitomycin | - |
dc.subject.keywordAuthor | refractory colon cancer | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
(02841) 서울특별시 성북구 안암로 14502-3290-1114
COPYRIGHT © 2021 Korea University. All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.